Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jun 9;17(1):180.
doi: 10.1186/s12884-017-1365-x.

Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial

Juliana Dos Santos Vaz  1 , Dayana Rodrigues Farias  2 , Amanda Rodrigues Amorim Adegboye  3 , Antonio Egidio Nardi  4 , Gilberto Kac  2
Affiliations
Randomized Controlled Trial

Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial

Juliana Dos Santos Vaz et al. BMC Pregnancy Childbirth. .

Abstract

Background: Low n-3 polyunsaturated fatty acids (PUFAs) has been linked to depression, but the preventive effect of n-3PUFAs supplementation on maternal depression needs further investigation. We aimed to evaluate the efficacy of a daily dose of n-3 PUFAs supplementation (fish oil) on the prevention of postpartum depression (PPD).

Methods: A randomized, placebo-controlled, double blind trial was designed and nested into a cohort study conducted in Rio de Janeiro, Brazil. Sixty pregnant women identified as being at risk for PPD were invited and randomly assigned to receive fish oil capsules [1.8 g (1.08 g of Eicosapentaenoic (EPA) and 0.72 g of Docosapentaenoic (DHA) acids)] or placebo (control). The Edinburgh Postnatal Depression Scale (EPDS) was scored at 5-13 (T0, baseline), 22-24 (T1), 30-32 weeks of gestation (T2) and 4-6 weeks' postpartum (T3). Supplementation started at week 22-24 of gestation (T1) and lasted for 16 weeks. Serum fatty acids were assayed to evaluate compliance. Prevalence of EPDS ≥11 was the primary outcome, and mean and changes in EPDS score, length of gestation, and birth weight the secondary outcomes. Linear mixed-effect (LME) and random-intercept logistic regression models were performed to test the effect of fish oil supplementation on prevalence of EPDS ≥11 and EPDS scores variation.

Results: In intention-to-treat (ITT) analysis, at 30-32 weeks' gestation women in the fish oil presented higher serum concentration of EPA, DHA and lower n-6/n-3 ratio comparing to the control group. There were no differences between intervention and control groups in the prevalence of EPDS ≥11, EPDS scores over time, or in changes in EPDS scores from pregnancy to postpartum in either the ITT or per-protocol analyses. Women in the fish oil group with previous history of depression presented a higher reduction on the EPDS score from the second to the third trimester in the fish oil comparing to the control group in the ITT analyses [-1.0 (-3.0-0.0) vs. -0.0 (-1.0-3.0), P = 0.038). These results were confirmed on the LME model (β = -3.441; 95%CI: -6.532- -0.350, P = 0.029).

Conclusion: Daily supplementation of 1.8 g of n-3 PUFAs during 16 weeks did not prevent maternal depressive symptoms in a sample of Brazilian women.

Trial registration: ClinicalTrials.gov Identifier: NCT01660165 . Retrospectively registered on 24 May 2012.

Keywords: Depression; pregnancy; Fatty acids; Omega-3; Randomized controlled trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow of participant through the randomized clinical trial
Fig. 2
Fig. 2
Longitudinal changes in EDPS score in women with previous history of depression according to intervention group (Intention-to-treat analysis). Note: T1 = 22–24 gestational weeks (Randomized Clinical Trial baseline); T2 = 30–32 gestational weeks; T3 = 4–6 weeks’ postpartum. Data are presented as linear mixed effect coefficient (β) and 95% CI. P-value refers to the maximum likelihood estimator. T1 was the reference category. Fish oil supplement group: β(T2) = −0.266; 95% CI = −2.428 to 1.896; P = 0.809. β(T3) = −2.665; 95% CI = −4.774 to −0.556; P = 0.013. Control group: β(T2) = 0.046; 95% CI = −2.118 to 2.210; P = 0.967. β(T3) = 0.891; 95% CI = −1.364 to 3.146; P = 0.439
See this image and copyright information in PMC

References

    1. Golding J, Steer C, Emmett P, Davis JM, Hibbeln JR. High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology. 2009;20(4):598–603. doi: 10.1097/EDE.0b013e31819d6a57. - DOI - PubMed
    1. Vaz Jdos S, Kac G, Emmett P, Davis JM, Golding J, Hibbeln JR. Dietary patterns, n-3 fatty acids intake from seafood and high levels of anxiety symptoms during pregnancy: findings from the Avon longitudinal study of parents and children. PLoS One. 2013;8(7):e67671. doi: 10.1371/journal.pone.0067671. - DOI - PMC - PubMed
    1. Hibbeln JR, Davis JM. Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2–3):179–186. doi: 10.1016/j.plefa.2009.06.005. - DOI - PMC - PubMed
    1. Gibson RA, Muhlhausler B, Makrides M. Conversion of linoleic acid and alpha-linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a focus on pregnancy, lactation and the first 2 years of life. Matern Child Nutr. 2011;7(Suppl 2):17–26. doi: 10.1111/j.1740-8709.2011.00299.x. - DOI - PMC - PubMed
    1. Brenna JT, Salem N, Jr, Sinclair AJ, Cunnane SC. Alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009;80(2–3):85–91. doi: 10.1016/j.plefa.2009.01.004. - DOI - PubMed

Publication types

MeSH terms

Associated data